5AM Solutions Adds Dr. Dan Von Hoff to Advisory Board

Share Article

5AM Solutions, a custom software developer for the life sciences, is pleased to announce that preeminent oncologist, Daniel D. Von Hoff, M.D. has been appointed to its advisory board. Dr. Von Hoff will provide insight into opportunities where software can tip the balance in the fight against cancer.

Dr. Von Hoff is a difference maker

5AM Solutions, a custom software developer for the life sciences, today announced the appointment of Daniel D. Von Hoff, MD, to its advisory board. Dr. Von Hoff will provide insight into opportunities where software can tip the balance in the fight against cancer, provide domain expertise and grant exposure to his network - all key drivers supporting the software firm's triple-digit growth.

"Dr. Von Hoff is a difference maker," said Brent Gendleman, 5AM's Chief Executive Officer and President. "He is a leader in the field of clinical oncology, and will be a tremendous sounding board and door opener. Sharing his expertise across business domains increases our capacity to provide software that solves life science business problems rather than introducing them. His dedication to curing cancer matches our own passion to increase access to quality software that will change the pace of progress."

Currently, Dr. Von Hoff is Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division. He also serves as Head, Pancreatic Cancer Research Program in Phoenix, Arizona, and is Chief Scientific Officer for US Oncology.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the early development of drugs that are now routinely used to treat cancer, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.

A prolific scientific writer, Dr. Von Hoff has published more than 529 papers, 129 book chapters, and more than 892 abstracts. His laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer.

Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004 - March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for many medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

About 5AM Solutions

5AM Solutions builds software targeting life science companies which view data organization, work-flow optimization, analysis, and global collaboration as key components of their success. Our web solutions grant insight into the complex data produced by the genomic revolution integrated with the directed collection of clinical data across geography, discipline and IT disparities found among collaborators around the globe or down the hall. An IBM Life Sciences Optimized partner, we share our clients' passion to advance medicine and science through our contribution of software that works. http://www.5amsolutions.com

Contact:

Brent Gendleman

602-722-1530 voice

1-888-577-8855 fax

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brent Gendleman
Visit website